Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview

Johnson & Johnson’s COVID-19 vaccine won’t be the first to reach the market, but it could be one of the most important. The company has made scientific and business decisions about the vaccine’s profile that, if it is demonstrated to be safe and effective, will maximize its utility in combating the pandemic.

The biggest differentiator is that unlike any other COVID-19 vaccine that has been authorized or is in late-stage development, Johnson & Johnson (NYSE:JNJ) designed its vaccine to provide robust, durable protection with a single dose. This will double inventories compared with two-dose vaccines. More importantly, a single dose dramatically reduces the complexity of the vaccine administration process by  eliminating the need for creating and maintaining systems to remind people to return for a second shot. ...